期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 9, 页码 6008-6020出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00085
关键词
-
资金
- National Natural Science Foundation of China [32072208]
JM was identified as an effective candidate for anti-triple-negative breast cancer, showing high selectivity against cancer cells without apparent toxicity to normal cells. Mechanistically, JM inhibits breast cancer cell growth through inducing apoptosis and altering the cell cycle. The downregulation of PI3K/Akt pathway by JM through suppressing PTP1B expression reveals its potential as an innovative therapeutic drug for TNBC.
Twenty-three natural jamunone analogues along with a series of jamunone-based derivatives were synthesized and evaluated for their inhibitory effects against breast cancer (BC) MDA-MB-231 and MCF-7 cells. The preliminary structure-activity relationship revealed that the length of aliphatic side chain and free phenolic hydroxyl group at the scaffold played a vital role in anti-BC activities and the methyl group on chromanone affected the selectivity of molecules against MDA-MB-231 and MCF-7 cells. Among them, jamunone M (JM) was screened as the most effective anti-triple-negative breast cancer (anti-TNBC) candidate with a high selectivity against BC cells over normal human cells. Mechanistic investigations indicated that JM could induce mitochondria-mediated apoptosis and cause G0/G1 phase arrest in BC cells. Furthermore, JM significantly restrained tumor growth in MDA-MB-231 xenograft mice without apparent toxicity. Interestingly, JM could downregulate phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression. These findings revealed the potential of JM as an appealing therapeutic drug candidate for TNBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据